( FR940405-1-00078 4 41 47 53 149
0.92.7 FR940405-1-00078 1 42
) FR940405-1-00078 3 43 49 55
dry/irritated/itchy FR940405-1-00078 2 44 183
eyes FR940405-1-00078 2 45 184
1.4 FR940405-1-00078 1 46
0.92.2 FR940405-1-00078 1 48
frequent FR940405-1-00078 1 50
headaches FR940405-1-00078 2 51 162
1.5 FR940405-1-00078 1 52
0.90.3 FR940405-1-00078 1 54
1study FR940405-1-00078 1 56
subjects FR940405-1-00078 1 57
were FR940405-1-00078 2 58 63
asked FR940405-1-00078 1 59
whether FR940405-1-00078 1 60
the FR940405-1-00078 4 61 125 132 156
symptoms FR940405-1-00078 1 62
occurring FR940405-1-00078 1 64
often FR940405-1-00078 1 65
or FR940405-1-00078 3 66 168 194
always FR940405-1-00078 1 67
at FR940405-1-00078 2 68 115
work FR940405-1-00078 2 69 75
and FR940405-1-00078 4 70 144 182 185
improving FR940405-1-00078 1 71
when FR940405-1-00078 1 72
away FR940405-1-00078 1 73
from FR940405-1-00078 1 74
. FR940405-1-00078 6 76 117 137 159 171 197
table FR940405-1-00078 1 77
iv FR940405-1-00078 1 78
12._ FR940405-1-00078 1 79
osha FR940405-1-00078 1 80
's FR940405-1-00078 1 81
estimates FR940405-1-00078 1 82
of FR940405-1-00078 4 83 110 127 141
risk FR940405-1-00078 4 84 116 120 158
for FR940405-1-00078 1 85
workers FR940405-1-00078 2 86 114
in FR940405-1-00078 2 87 131
airconditioned FR940405-1-00078 2 88 128
buildings1 FR940405-1-00078 1 89
1 FR940405-1-00078 1 90
1annual FR940405-1-00078 1 91
risk2 FR940405-1-00078 1 92
1lifetime FR940405-1-00078 1 93
occupational FR940405-1-00078 2 94 142
risk3 FR940405-1-00078 1 95
severe FR940405-1-00078 2 96 187
headaches4 FR940405-1-00078 1 97
1.296 FR940405-1-00078 1 98
57 FR940405-1-00078 1 99
upper FR940405-1-00078 1 100
respiratory FR940405-1-00078 1 101
symptoms5 FR940405-1-00078 1 102
1.969 FR940405-1-00078 1 103
85 FR940405-1-00078 1 104
1risks FR940405-1-00078 1 105
are FR940405-1-00078 1 106
expressed FR940405-1-00078 1 107
as FR940405-1-00078 4 108 147 161 173
number FR940405-1-00078 1 109
cases FR940405-1-00078 1 111
per FR940405-1-00078 1 112
1000 FR940405-1-00078 1 113
2the FR940405-1-00078 1 118
annual FR940405-1-00078 2 119 157
is FR940405-1-00078 4 121 134 145 155
estimated FR940405-1-00078 1 122
assuming FR940405-1-00078 1 123
that FR940405-1-00078 2 124 163
prevalence FR940405-1-00078 1 126
office FR940405-1-00078 1 129
buildings FR940405-1-00078 1 130
us FR940405-1-00078 1 133
70 FR940405-1-00078 1 135
percent FR940405-1-00078 1 136
3assumes FR940405-1-00078 1 138
45 FR940405-1-00078 2 139 151
years FR940405-1-00078 1 140
exposure FR940405-1-00078 1 143
calculated FR940405-1-00078 1 146
1- FR940405-1-00078 1 148
, FR940405-1-00078 4 150 152 176 179
where FR940405-1-00078 1 153
p FR940405-1-00078 1 154
4defined FR940405-1-00078 1 160
either FR940405-1-00078 2 164 190
require FR940405-1-00078 2 165 191
medical FR940405-1-00078 2 166 192
attention FR940405-1-00078 2 167 193
restrict FR940405-1-00078 2 169 195
activity FR940405-1-00078 2 170 196
5defined FR940405-1-00078 1 172
runny FR940405-1-00078 1 174
nose FR940405-1-00078 2 175 178
stuffy FR940405-1-00078 1 177
dry/irritated FR940405-1-00078 1 180
throat FR940405-1-00078 1 181
being FR940405-1-00078 1 186
enough FR940405-1-00078 1 188
to FR940405-1-00078 1 189
f. FR940405-1-00079 1 0
pharmacokinetic FR940405-1-00079 2 1 23
modeling FR940405-1-00079 1 2
of FR940405-1-00079 33 3 19 38 53 83 102 110 131 134 137 158 165 174 178 186 214 223 246 250 262 282 288 302 326 339 370 373 430 438 463 478 483 489
ets FR940405-1-00079 12 4 58 119 127 224 295 306 340 374 400 439 484
exposure FR940405-1-00079 12 5 44 59 117 125 138 180 225 247 296 322 398
in FR940405-1-00079 11 6 28 112 161 169 198 206 217 255 336 467
developing FR940405-1-00079 1 7
a FR940405-1-00079 16 8 20 33 221 243 251 259 280 303 307 332 367 435 443 450 473
final FR940405-1-00079 1 9
rule FR940405-1-00079 1 10
, FR940405-1-00079 29 11 46 71 74 142 145 171 189 200 230 232 234 236 241 270 272 274 310 316 341 347 375 410 412 447 454 472 494 496
osha FR940405-1-00079 3 12 64 84
would FR940405-1-00079 3 13 181 485
like FR940405-1-00079 1 14
to FR940405-1-00079 15 15 31 57 87 96 107 118 126 155 210 311 323 331 353 399
consider FR940405-1-00079 1 16
the FR940405-1-00079 23 17 61 77 94 108 122 129 135 162 172 207 211 263 283 286 312 319 324 337 371 378 464 476
use FR940405-1-00079 7 18 109 130 173 213 477 488
physiologically FR940405-1-00079 1 21
based FR940405-1-00079 2 22 151
( FR940405-1-00079 4 24 381 407 420
pbpk FR940405-1-00079 1 25
) FR940405-1-00079 4 26 383 409 422
model FR940405-1-00079 1 27
an FR940405-1-00079 5 29 81 91 175 291
effort FR940405-1-00079 1 30
develop FR940405-1-00079 1 32
clear FR940405-1-00079 1 34
and FR940405-1-00079 11 35 50 90 275 328 356 376 413 455 470 497
complete FR940405-1-00079 1 36
picture FR940405-1-00079 1 37
factors FR940405-1-00079 1 39
that FR940405-1-00079 1 40
may FR940405-1-00079 2 41 363
affect FR940405-1-00079 1 42
environmental FR940405-1-00079 2 43 187
measurements FR940405-1-00079 3 45 185 249
internal FR940405-1-00079 3 47 176 292
dose FR940405-1-00079 1 48
estimates FR940405-1-00079 2 49 52
ultimately FR940405-1-00079 1 51
expected FR940405-1-00079 1 54
risk FR940405-1-00079 3 55 115 123
attributed FR940405-1-00079 1 56
at FR940405-1-00079 1 60
workplace FR940405-1-00079 1 62
. FR940405-1-00079 17 63 76 120 139 168 197 228 239 277 297 335 359 390 425 428 461 499
is FR940405-1-00079 5 65 279 432 442 449
seeking FR940405-1-00079 1 66
comment FR940405-1-00079 2 67 98
on FR940405-1-00079 4 68 99 152 459
appropriate FR940405-1-00079 2 69 379
methodology FR940405-1-00079 1 70
available FR940405-1-00079 1 72
data FR940405-1-00079 1 73
etc FR940405-1-00079 1 75
following FR940405-1-00079 2 78 278
discussion FR940405-1-00079 1 79
offers FR940405-1-00079 1 80
explanation FR940405-1-00079 1 82
's FR940405-1-00079 4 85 253 265 321
approach FR940405-1-00079 1 86
this FR940405-1-00079 1 88
issue FR940405-1-00079 1 89
opportunity FR940405-1-00079 1 92
for FR940405-1-00079 8 93 294 300 305 384 475 480 492
agency FR940405-1-00079 1 95
solicit FR940405-1-00079 1 97
specific FR940405-1-00079 2 100 333
points FR940405-1-00079 1 101
concern FR940405-1-00079 2 103 327
as FR940405-1-00079 4 104 191 220 290
they FR940405-1-00079 1 105
relate FR940405-1-00079 1 106
pharmacokinetics FR940405-1-00079 2 111 266
estimating FR940405-1-00079 2 113 121
occupational FR940405-1-00079 1 114
from FR940405-1-00079 5 116 124 148 248 397
requires FR940405-1-00079 2 128 258
some FR940405-1-00079 1 132
measure FR940405-1-00079 2 133 177
extent FR940405-1-00079 2 136 314
possible FR940405-1-00079 3 140 212 315
measures FR940405-1-00079 1 141
or FR940405-1-00079 2 143 194
metrics FR940405-1-00079 1 144
can FR940405-1-00079 1 146
range FR940405-1-00079 1 147
categorical FR940405-1-00079 1 149
ranking FR940405-1-00079 1 150
survey FR940405-1-00079 1 153
responses FR940405-1-00079 1 154
direct FR940405-1-00079 1 156
measurement FR940405-1-00079 1 157
etsrelated FR940405-1-00079 1 159
chemicals FR940405-1-00079 1 160
body FR940405-1-00079 3 163 218 256
fluids FR940405-1-00079 3 164 219 257
exposed FR940405-1-00079 1 166
individuals FR940405-1-00079 1 167
general FR940405-1-00079 1 170
individual FR940405-1-00079 2 179 320
be FR940405-1-00079 3 182 364 388
preferred FR940405-1-00079 1 183
over FR940405-1-00079 1 184
contamination FR940405-1-00079 1 188
such FR940405-1-00079 1 190
airborne FR940405-1-00079 1 192
chemical FR940405-1-00079 3 193 252 264
particulate FR940405-1-00079 1 195
concentrations FR940405-1-00079 2 196 216
particular FR940405-1-00079 1 199
considerable FR940405-1-00079 1 201
attention FR940405-1-00079 2 202 350
has FR940405-1-00079 1 203
been FR940405-1-00079 2 204 402
given FR940405-1-00079 2 205 352
scientific FR940405-1-00079 1 208
literature FR940405-1-00079 1 209
cotinine FR940405-1-00079 2 215 289
biomarker FR940405-1-00079 5 222 293 304 308 380
[ FR940405-1-00079 2 226 423
exs FR940405-1-00079 1 227
424 FR940405-1-00079 1 229
4146 FR940405-1-00079 1 231
4165 FR940405-1-00079 1 233
4263 FR940405-1-00079 1 235
4316 FR940405-1-00079 1 237
] FR940405-1-00079 2 238 427
however FR940405-1-00079 1 240
obtaining FR940405-1-00079 1 242
dependable FR940405-1-00079 1 244
estimate FR940405-1-00079 1 245
concentration FR940405-1-00079 1 254
quantitative FR940405-1-00079 1 260
understanding FR940405-1-00079 1 261
; FR940405-1-00079 2 267 440
its FR940405-1-00079 1 268
uptake FR940405-1-00079 1 269
distribution FR940405-1-00079 1 271
metabolism FR940405-1-00079 1 273
excretion FR940405-1-00079 1 276
review FR940405-1-00079 1 281
evidence FR940405-1-00079 1 284
concerning FR940405-1-00079 1 285
suitability FR940405-1-00079 1 287
1. FR940405-1-00079 1 298
considerations FR940405-1-00079 1 299
selection FR940405-1-00079 1 301
should FR940405-1-00079 1 309
greatest FR940405-1-00079 1 313
accurately FR940405-1-00079 1 317
represent FR940405-1-00079 1 318
substance FR940405-1-00079 1 325
have FR940405-1-00079 2 329 401
relevance FR940405-1-00079 1 330
endpoint FR940405-1-00079 3 334 362 386
case FR940405-1-00079 1 338
there FR940405-1-00079 1 342
are FR940405-1-00079 2 343 457
several FR940405-1-00079 1 344
relevant FR940405-1-00079 1 345
endpoints FR940405-1-00079 1 346
with FR940405-1-00079 4 348 404 416 434
principal FR940405-1-00079 1 349
being FR940405-1-00079 1 351
heart FR940405-1-00079 1 354
disease FR940405-1-00079 1 355
lung FR940405-1-00079 1 357
cancer FR940405-1-00079 1 358
each FR940405-1-00079 3 360 385 429
different FR940405-1-00079 4 361 368 389 436
mediated FR940405-1-00079 1 365
by FR940405-1-00079 1 366
subset FR940405-1-00079 1 369
components FR940405-1-00079 1 372
therefore FR940405-1-00079 1 377
s FR940405-1-00079 1 382
could FR940405-1-00079 1 387
2. FR940405-1-00079 1 391
cardiovascular FR940405-1-00079 3 392 394 481
effects FR940405-1-00079 3 393 395 482
resulting FR940405-1-00079 1 396
associated FR940405-1-00079 2 403 433
carbon FR940405-1-00079 1 405
monoxide FR940405-1-00079 1 406
co FR940405-1-00079 3 408 441 493
nicotine FR940405-1-00079 3 411 448 495
more FR940405-1-00079 1 414
recently FR940405-1-00079 1 415
polycyclic FR940405-1-00079 1 417
aromatic FR940405-1-00079 1 418
hydrocarbons FR940405-1-00079 1 419
pahs FR940405-1-00079 3 421 456 498
ex FR940405-1-00079 1 424
4123 FR940405-1-00079 1 426
these FR940405-1-00079 1 431
fraction FR940405-1-00079 1 437
gas FR940405-1-00079 1 444
phase FR940405-1-00079 1 445
constituent FR940405-1-00079 1 446
low FR940405-1-00079 1 451
volatility FR940405-1-00079 1 452
vapor FR940405-1-00079 1 453
absorbed FR940405-1-00079 1 458
particulates FR940405-1-00079 1 460
because FR940405-1-00079 1 462
significant FR940405-1-00079 1 465
differences FR940405-1-00079 1 466
physical FR940405-1-00079 1 468
fate FR940405-1-00079 1 469
transport FR940405-1-00079 1 471
strategy FR940405-1-00079 1 474
biomarkers FR940405-1-00079 1 479
ideally FR940405-1-00079 1 486
make FR940405-1-00079 1 487
separate FR940405-1-00079 1 490
markers FR940405-1-00079 1 491
the FR940405-1-00080 47 0 31 40 77 90 98 110 147 160 177 188 208 221 259 276 301 337 381 398 418 439 459 465 487 502 508 540 568 571 587 600 612 616 630 656 665 684 692 723 744 878 883 982 992 995 1000 1064
most FR940405-1-00080 5 1 302 379 488 503
common FR940405-1-00080 1 2
internal FR940405-1-00080 4 3 269 704 736
measure FR940405-1-00080 5 4 20 51 330 412
of FR940405-1-00080 59 5 21 34 43 79 92 95 133 150 162 180 190 210 228 265 278 322 331 339 359 380 385 397 413 422 462 467 469 478 506 510 525 530 548 565 573 589 602 615 619 627 636 640 658 668 677 686 694 699 726 739 816 918 936 969 984 997 1037 1046
co FR940405-1-00080 8 6 24 47 53 66 80 96 284
exposure FR940405-1-00080 17 7 22 48 324 333 342 414 484 531 662 708 784 803 822 839 971 1075
is FR940405-1-00080 18 8 49 89 176 205 249 271 345 472 515 608 645 689 730 753 771 938 994
blood FR940405-1-00080 3 9 15 57
carboxyhemoglobin FR940405-1-00080 1 10
( FR940405-1-00080 5 11 283 313 367 606
hbco FR940405-1-00080 4 12 16 58 82
) FR940405-1-00080 5 13 290 316 376 621
. FR940405-1-00080 50 14 69 72 100 126 129 159 183 197 234 256 275 297 334 392 417 457 486 520 552 555 577 582 622 674 728 748 751 766 769 785 825 828 848 859 867 874 907 910 928 946 949 974 991 1002 1025 1032 1060 1063 1080
provides FR940405-1-00080 2 17 501
a FR940405-1-00080 27 18 36 60 73 84 156 163 252 319 328 357 410 492 560 646 680 697 720 754 773 787 797 834 956 987 1035 1069
useful FR940405-1-00080 1 19
to FR940405-1-00080 32 23 30 38 50 116 166 170 231 294 309 343 390 455 474 518 537 591 604 610 638 671 690 709 795 812 840 896 901 923 941 1017 1042
, FR940405-1-00080 49 25 119 131 145 218 223 226 251 258 285 287 348 371 373 377 394 433 441 451 512 532 579 586 624 642 655 696 701 711 713 716 790 804 850 852 855 862 869 871 877 931 962 1005 1008 1010 1013 1027 1029 1034
and FR940405-1-00080 29 26 55 109 146 173 219 224 288 374 431 442 448 513 543 570 643 653 712 760 782 805 807 842 863 887 932 963 1011 1076
can FR940405-1-00080 7 27 102 113 142 152 893 965
be FR940405-1-00080 14 28 103 114 143 153 295 308 481 498 611 672 796 813 894
related FR940405-1-00080 4 29 115 402 940
cardiovascular FR940405-1-00080 1 32
effects FR940405-1-00080 6 33 88 118 618 667 725
co. FR940405-1-00080 1 35
way FR940405-1-00080 1 37
determine FR940405-1-00080 1 39
occupational FR940405-1-00080 1 41
component FR940405-1-00080 1 42
one FR940405-1-00080 3 44 235 499
's FR940405-1-00080 1 45
total FR940405-1-00080 1 46
workplace FR940405-1-00080 2 52 99
levels FR940405-1-00080 7 54 175 763 917 925 943 1052
predict FR940405-1-00080 1 56
with FR940405-1-00080 4 59 76 216 981
physiologically FR940405-1-00080 1 61
based FR940405-1-00080 1 62
pharmacokinetic FR940405-1-00080 4 63 157 164 260
model FR940405-1-00080 3 64 158 165
for FR940405-1-00080 17 65 86 202 246 263 483 491 664 682 706 722 800 891 898 959 989 1053
[ FR940405-1-00080 15 67 124 550 575 746 764 823 846 857 865 905 926 944 1023 1058
ex FR940405-1-00080 11 68 125 551 747 765 824 858 906 927 945 1059
411 FR940405-1-00080 1 70
] FR940405-1-00080 15 71 128 554 581 750 768 827 854 861 873 909 930 948 1031 1062
difficulty FR940405-1-00080 1 74
associated FR940405-1-00080 3 75 215 980
use FR940405-1-00080 7 78 161 264 277 657 693 983
or FR940405-1-00080 5 81 137 314 401 597
as FR940405-1-00080 23 83 121 242 267 318 325 327 365 429 438 446 594 596 660 679 702 714 719 734 818 820 967 986
biomarker FR940405-1-00080 8 85 201 270 493 681 705 737 988
ets FR940405-1-00080 27 87 217 323 344 355 386 391 416 423 470 479 511 519 549 574 620 641 669 683 727 783 802 841 902 970 990 1074
presence FR940405-1-00080 3 91 209 996
other FR940405-1-00080 1 93
sources FR940405-1-00080 1 94
in FR940405-1-00080 19 97 106 135 139 187 404 494 521 567 583 629 779 786 844 875 903 972 999 1020
nicotine FR940405-1-00080 20 101 134 151 169 172 312 332 534 566 590 628 659 700 710 733 758 886 960 998 1019
measured FR940405-1-00080 3 104 144 778
directly FR940405-1-00080 2 105 921
body FR940405-1-00080 4 107 140 745 780
fluids FR940405-1-00080 5 108 141 406 781 954
circulating FR940405-1-00080 3 111 148 171
concentration FR940405-1-00080 2 112 149
physiological FR940405-1-00080 1 117
such FR940405-1-00080 5 120 428 437 445 715
heart FR940405-1-00080 1 122
rate FR940405-1-00080 1 123
426 FR940405-1-00080 1 127
alternatively FR940405-1-00080 1 130
measurements FR940405-1-00080 4 132 564 626 635
air FR940405-1-00080 3 136 569 631
cotinine FR940405-1-00080 17 138 174 315 678 695 729 762 777 792 809 843 888 919 937 985 1051 1078
inferred FR940405-1-00080 1 154
using FR940405-1-00080 1 155
relate FR940405-1-00080 1 167
inhaled FR940405-1-00080 2 168 186
main FR940405-1-00080 1 178
focus FR940405-1-00080 1 179
this FR940405-1-00080 3 181 495 687
section FR940405-1-00080 2 182 688
pahs FR940405-1-00080 6 184 204 211 229 286 447
are FR940405-1-00080 6 185 195 387 453 920 976
form FR940405-1-00080 1 189
particulates FR940405-1-00080 4 191 213 248 456
on FR940405-1-00080 5 192 212 311 464 1049
which FR940405-1-00080 7 193 238 361 452 476 500 514
they FR940405-1-00080 1 194
adsorbed FR940405-1-00080 2 196 230
developing FR940405-1-00080 1 198
an FR940405-1-00080 8 199 243 268 522 661 703 735 1044
appropriate FR940405-1-00080 1 200
etsassociated FR940405-1-00080 2 203 247
complicated FR940405-1-00080 1 206
by FR940405-1-00080 2 207 220
not FR940405-1-00080 6 214 272 292 346 388 408
low FR940405-1-00080 1 222
variable FR940405-1-00080 1 225
composition FR940405-1-00080 1 227
particulate FR940405-1-00080 2 232 544
matter FR940405-1-00080 1 233
candidate FR940405-1-00080 1 236
material FR940405-1-00080 1 237
has FR940405-1-00080 2 239 351
been FR940405-1-00080 4 240 352 363 1015
suggested FR940405-1-00080 1 241
environmental FR940405-1-00080 2 244 528
marker FR940405-1-00080 4 245 321 663 799
solanesol FR940405-1-00080 3 250 266 289
none FR940405-1-00080 2 253 443
tobacco FR940405-1-00080 1 254
constituent FR940405-1-00080 2 255 547
however FR940405-1-00080 2 257 1033
information FR940405-1-00080 2 261 463
necessary FR940405-1-00080 1 262
currently FR940405-1-00080 3 273 305 879
available FR940405-1-00080 2 274 880
these FR940405-1-00080 2 279 584
three FR940405-1-00080 2 280 952
different FR940405-1-00080 1 281
biomarkers FR940405-1-00080 3 282 403 968
does FR940405-1-00080 1 291
appear FR940405-1-00080 1 293
practical FR940405-1-00080 1 296
it FR940405-1-00080 3 298 350 471
appears FR940405-1-00080 2 299 670
that FR940405-1-00080 5 300 354 885 915 933
effective FR940405-1-00080 1 303
strategy FR940405-1-00080 1 304
achievable FR940405-1-00080 1 306
would FR940405-1-00080 3 307 407 497
rely FR940405-1-00080 1 310
measurement FR940405-1-00080 2 317 396
specific FR940405-1-00080 1 320
well FR940405-1-00080 2 326 819
direct FR940405-1-00080 2 329 395
3. FR940405-1-00080 1 335
carcinogenicity FR940405-1-00080 4 336 340 468 654
mechanism FR940405-1-00080 2 338 466
from FR940405-1-00080 3 341 415 743
known FR940405-1-00080 1 347
but FR940405-1-00080 1 349
established FR940405-1-00080 1 353
includes FR940405-1-00080 1 356
number FR940405-1-00080 1 358
chemicals FR940405-1-00080 4 360 427 436 444
have FR940405-1-00080 5 362 558 831 912 1014
identified FR940405-1-00080 2 364 382
carcinogens FR940405-1-00080 1 366
see FR940405-1-00080 1 368
tables FR940405-1-00080 1 369
ii2 FR940405-1-00080 1 370
iii6 FR940405-1-00080 1 372
iii7 FR940405-1-00080 1 375
although FR940405-1-00080 1 378
carcinogenic FR940405-1-00080 5 383 399 420 617 666
components FR940405-1-00080 5 384 400 421 477 509
unique FR940405-1-00080 3 389 411 517
therefore FR940405-1-00080 2 393 623
biological FR940405-1-00080 2 405 953
provide FR940405-1-00080 2 409 955
potentially FR940405-1-00080 1 419
include FR940405-1-00080 1 424
highly FR940405-1-00080 1 425
volatile FR940405-1-00080 1 426
formaldehyde FR940405-1-00080 1 430
benzene FR940405-1-00080 1 432
lower FR940405-1-00080 1 434
volatility FR940405-1-00080 1 435
nitrosamines FR940405-1-00080 1 440
metal FR940405-1-00080 1 449
compounds FR940405-1-00080 1 450
bound FR940405-1-00080 1 454
given FR940405-1-00080 1 458
current FR940405-1-00080 1 460
lack FR940405-1-00080 1 461
impossible FR940405-1-00080 1 473
identify FR940405-1-00080 1 475
should FR940405-1-00080 1 480
targeted FR940405-1-00080 1 482
estimation FR940405-1-00080 1 485
prudent FR940405-1-00080 1 489
choice FR940405-1-00080 1 490
case FR940405-1-00080 1 496
general FR940405-1-00080 2 504 876
representation FR940405-1-00080 1 505
all FR940405-1-00080 2 507 951
itself FR940405-1-00080 1 516
experimental FR940405-1-00080 1 523
study FR940405-1-00080 4 524 789 1036 1066
potential FR940405-1-00080 2 526 978
etsunique FR940405-1-00080 1 527
markers FR940405-1-00080 1 529
only FR940405-1-00080 1 533
was FR940405-1-00080 4 535 593 793 1040
found FR940405-1-00080 3 536 794 811
represent FR940405-1-00080 1 538
both FR940405-1-00080 1 539
gas FR940405-1-00080 1 541
phase FR940405-1-00080 2 542 545
organic FR940405-1-00080 1 546
497 FR940405-1-00080 1 553
several FR940405-1-00080 3 556 829 1003
studies FR940405-1-00080 4 557 585 830 911
shown FR940405-1-00080 2 559 1016
strong FR940405-1-00080 4 561 755 774 1070
correlation FR940405-1-00080 5 562 648 756 775 1071
between FR940405-1-00080 6 563 649 757 776 837 1072
mutagenicity FR940405-1-00080 5 572 592 605 639 651
exs FR940405-1-00080 4 576 847 866 1024
4198 FR940405-1-00080 1 578
4215 FR940405-1-00080 1 580
relationship FR940405-1-00080 3 588 601 836
good FR940405-1-00080 2 595 814
better FR940405-1-00080 2 598 633
than FR940405-1-00080 2 599 634
rsp FR940405-1-00080 3 603 607 637
assumed FR940405-1-00080 1 609
major FR940405-1-00080 1 613
contributor FR940405-1-00080 1 614
since FR940405-1-00080 1 625
correlate FR940405-1-00080 1 632
there FR940405-1-00080 4 644 752 770 975
positive FR940405-1-00080 2 647 835
shortterm FR940405-1-00080 1 650
tests FR940405-1-00080 1 652
justified FR940405-1-00080 1 673
4. FR940405-1-00080 1 675
evaluation FR940405-1-00080 1 676
purpose FR940405-1-00080 1 685
discuss FR940405-1-00080 1 691
metabolite FR940405-1-00080 1 698
inhalation FR940405-1-00080 1 707
its FR940405-1-00080 2 717 740
usefulness FR940405-1-00080 1 718
metric FR940405-1-00080 2 721 958
health FR940405-1-00080 1 724
preferred FR940405-1-00080 1 731
over FR940405-1-00080 1 732
because FR940405-1-00080 1 738
slower FR940405-1-00080 1 741
clearance FR940405-1-00080 1 742
471 FR940405-1-00080 1 749
intake FR940405-1-00080 2 759 961
plasma FR940405-1-00080 4 761 806 924 942
4115 FR940405-1-00080 1 767
also FR940405-1-00080 3 772 832 913
controlled FR940405-1-00080 1 788
urinary FR940405-1-00080 2 791 934
reliable FR940405-1-00080 1 798
longterm FR940405-1-00080 2 801 821
salivary FR940405-1-00080 2 808 916
were FR940405-1-00080 1 810
indicators FR940405-1-00080 1 815
short- FR940405-1-00080 1 817
473 FR940405-1-00080 2 826 929
demonstrated FR940405-1-00080 2 833 914
selfreported FR940405-1-00080 3 838 1054 1073
serum FR940405-1-00080 3 845 1050 1077
4166 FR940405-1-00080 3 849 860 868
4250 FR940405-1-00080 1 851
4301 FR940405-1-00080 2 853 1061
saliva FR940405-1-00080 1 856
urine FR940405-1-00080 1 864
4211 FR940405-1-00080 1 870
4316 FR940405-1-00080 1 872
data FR940405-1-00080 1 881
support FR940405-1-00080 1 882
assumption FR940405-1-00080 1 884
kinetics FR940405-1-00080 1 889
parameters FR940405-1-00080 1 890
smokers FR940405-1-00080 1 892
extrapolated FR940405-1-00080 1 895
nonsmokers FR940405-1-00080 4 897 904 973 1039
estimating FR940405-1-00080 1 899
exposures FR940405-1-00080 1 900
424 FR940405-1-00080 1 908
proportional FR940405-1-00080 1 922
excretion FR940405-1-00080 1 935
linearly FR940405-1-00080 1 939
482 FR940405-1-00080 1 947
thus FR940405-1-00080 2 950 964
reasonable FR940405-1-00080 1 957
serve FR940405-1-00080 1 966
two FR940405-1-00080 1 977
difficulties FR940405-1-00080 1 979
first FR940405-1-00080 1 993
diet FR940405-1-00080 1 1001
foods FR940405-1-00080 1 1004
including FR940405-1-00080 1 1006
tea FR940405-1-00080 3 1007 1047 1056
tomatoes FR940405-1-00080 1 1009
potatoes FR940405-1-00080 1 1012
contain FR940405-1-00080 1 1018
measurable FR940405-1-00080 1 1021
quantities FR940405-1-00080 1 1022
449 FR940405-1-00080 1 1026
481 FR940405-1-00080 1 1028
4281 FR940405-1-00080 1 1030
3383 FR940405-1-00080 1 1038
unable FR940405-1-00080 1 1041
substantiate FR940405-1-00080 1 1043
effect FR940405-1-00080 1 1045
drinking FR940405-1-00080 1 1048
daily FR940405-1-00080 1 1055
consumption FR940405-1-00080 1 1057
same FR940405-1-00080 1 1065
did FR940405-1-00080 1 1067
find FR940405-1-00080 1 1068
level FR940405-1-00080 1 1079
osha FR940405-1-00081 2 0 130
seeks FR940405-1-00081 2 1 131
comment FR940405-1-00081 2 2 132
and FR940405-1-00081 36 3 144 256 281 295 310 339 341 359 391 398 423 443 488 512 542 549 584 607 650 681 757 778 827 837 849 881 892 903 952 980 1029 1034 1039 1173 1195
data FR940405-1-00081 3 4 255 601
on FR940405-1-00081 5 5 133 602 851 1145
whether FR940405-1-00081 1 6
dietary FR940405-1-00081 3 7 745 948
intake FR940405-1-00081 3 8 746 949
of FR940405-1-00081 77 9 36 53 66 94 118 139 159 208 215 237 253 261 293 323 337 344 370 383 388 394 420 427 436 440 451 456 478 533 555 581 605 624 629 637 662 669 688 694 710 721 728 733 741 744 747 759 766 814 818 825 842 846 854 884 895 910 915 921 930 950 958 964 993 1022 1032 1037 1044 1052 1073 1080 1082 1087 1107 1130 1160 1164
nicotine FR940405-1-00081 28 10 19 67 143 197 294 338 384 421 442 452 457 480 493 548 556 583 606 612 683 748 826 885 896 951 953 1023 1038
should FR940405-1-00081 1 11
be FR940405-1-00081 13 12 127 162 232 377 668 699 716 797 924 975 1117 1184
considered FR940405-1-00081 2 13 925
a FR940405-1-00081 28 14 39 47 166 218 223 320 405 416 424 433 476 530 538 644 655 663 731 767 800 888 893 913 940 1071 1078 1131 1134
significant FR940405-1-00081 3 15 972 1012
factor FR940405-1-00081 1 16
in FR940405-1-00081 28 17 99 346 349 357 458 482 496 509 557 609 618 671 678 752 774 829 857 898 906 956 1014 1019 1054 1092 1111 1123 1175
modelling FR940405-1-00081 1 18
metabolism FR940405-1-00081 1 20
for FR940405-1-00081 20 21 50 142 146 205 300 445 507 632 659 701 771 874 984 1005 1050 1133 1157 1167 1179
assessing FR940405-1-00081 1 22
risk FR940405-1-00081 5 23 941 982 1007 1112
due FR940405-1-00081 1 24
to FR940405-1-00081 28 25 97 113 126 189 195 267 333 376 474 490 528 546 715 717 725 749 785 802 834 863 938 976 1000 1025 1095 1104 1154
ets FR940405-1-00081 8 26 98 633 734 782 835 868 916
exposure FR940405-1-00081 11 27 96 634 735 783 833 869 886 917 978 1169
. FR940405-1-00081 46 28 73 82 104 129 136 173 182 201 204 234 287 290 305 314 319 328 348 404 412 429 453 499 517 520 561 564 570 586 626 684 705 794 870 905 926 943 955 989 1009 1041 1058 1084 1100 1142 1156
the FR940405-1-00081 61 29 34 42 51 63 92 100 115 157 183 209 213 235 238 250 257 352 368 392 437 454 483 521 603 619 622 638 660 673 689 695 706 726 742 753 815 843 852 871 899 908 927 962 966 985 990 1002 1006 1010 1020 1030 1105 1120 1125 1146 1158 1162 1171 1176 1180 1190
second FR940405-1-00081 2 30 991
issue FR940405-1-00081 3 31 135 1106
associated FR940405-1-00081 4 32 61 211 780
with FR940405-1-00081 11 33 62 165 212 264 363 464 599 781 831 1077
use FR940405-1-00081 7 35 214 508 670 727 853 909
cotinine FR940405-1-00081 32 37 54 145 160 193 216 296 324 340 345 354 371 389 395 428 444 534 550 585 608 617 625 676 729 750 772 828 855 911 1027 1040 1053
as FR940405-1-00081 14 38 156 217 271 535 537 614 616 730 791 799 912 1101 1119
biomarker FR940405-1-00081 4 40 219 732 914
is FR940405-1-00081 7 41 46 109 124 543 1047 1090
possibility FR940405-1-00081 1 43
that FR940405-1-00081 1 44
there FR940405-1-00081 2 45 108
longer FR940405-1-00081 2 48 84
halflife FR940405-1-00081 2 49 85
elimination FR940405-1-00081 1 52
at FR940405-1-00081 3 55 86 105
very FR940405-1-00081 2 56 87
low FR940405-1-00081 4 57 88 822 832
biological FR940405-1-00081 1 58
concentrations FR940405-1-00081 6 59 89 198 677 773 856
, FR940405-1-00081 50 60 75 77 79 121 149 175 177 179 220 222 247 274 277 280 307 316 351 366 390 470 485 487 541 589 594 649 686 755 776 821 859 887 891 901 918 961 968 973 1028 1060 1062 1064 1066 1069 1076 1114 1144 1149 1170
slow FR940405-1-00081 1 64
release FR940405-1-00081 1 65
from FR940405-1-00081 5 68 242 807 1098 1152
binding FR940405-1-00081 5 69 481 824 897 954
sites FR940405-1-00081 1 70
[ FR940405-1-00081 12 71 171 199 285 303 312 326 410 515 559 568 1056
exs FR940405-1-00081 4 72 172 304 313
428 FR940405-1-00081 1 74
424 FR940405-1-00081 3 76 176 1059
4167 FR940405-1-00081 1 78
4254 FR940405-1-00081 3 80 315 518
] FR940405-1-00081 12 81 181 203 289 309 318 330 414 519 563 572 1068
this FR940405-1-00081 10 83 106 119 134 430 500 587 795 1015 1093
could FR940405-1-00081 3 90 667 936
have FR940405-1-00081 2 91 297
effect FR940405-1-00081 3 93 120 967
overestimating FR940405-1-00081 1 95
lowest FR940405-1-00081 1 101
exposed FR940405-1-00081 2 102 987
population FR940405-1-00081 1 103
time FR940405-1-00081 2 107 355
not FR940405-1-00081 1 110
sufficient FR940405-1-00081 1 111
evidence FR940405-1-00081 1 112
quantify FR940405-1-00081 1 114
potential FR940405-1-00081 4 116 283 816 844
magnitude FR940405-1-00081 1 117
but FR940405-1-00081 2 122 367
it FR940405-1-00081 5 123 471 970 1089 1102
likely FR940405-1-00081 1 125
small FR940405-1-00081 1 128
5. FR940405-1-00081 1 137
description FR940405-1-00081 8 138 230 419 426 435 477 532 894
pharmacokinetic FR940405-1-00081 7 140 226 630 847 1109 1165 1181
models FR940405-1-00081 5 141 292 640 690 1182
many FR940405-1-00081 1 147
purposes FR940405-1-00081 1 148
an FR940405-1-00081 5 150 703 719 865 1042
essentially FR940405-1-00081 1 151
first FR940405-1-00081 3 152 465 928
order FR940405-1-00081 2 153 466
process FR940405-1-00081 1 154
such FR940405-1-00081 5 155 269 702 945 1045
kinetics FR940405-1-00081 8 158 365 422 439 467 551 593 604
can FR940405-1-00081 4 161 796 1116 1183
effectively FR940405-1-00081 1 163
modeled FR940405-1-00081 1 164
simple FR940405-1-00081 1 167
compartmental FR940405-1-00081 3 168 184 425
kinetic FR940405-1-00081 1 169
analysis FR940405-1-00081 4 170 704 720 1086
427 FR940405-1-00081 1 174
473 FR940405-1-00081 2 178 1061
482 FR940405-1-00081 2 180 1063
approach FR940405-1-00081 2 185 240
has FR940405-1-00081 4 186 503 524 573
been FR940405-1-00081 5 187 298 505 526 575
used FR940405-1-00081 1 188
relate FR940405-1-00081 1 190
steadystate FR940405-1-00081 1 191
urinary FR940405-1-00081 2 192 1035
levels FR940405-1-00081 2 194 751
atmospheric FR940405-1-00081 1 196
ex FR940405-1-00081 8 200 286 327 411 516 560 569 1057
4263 FR940405-1-00081 1 202
investigating FR940405-1-00081 1 206
some FR940405-1-00081 1 207
concerns FR940405-1-00081 1 210
however FR940405-1-00081 3 221 469 685
physiologically FR940405-1-00081 2 224 417
based FR940405-1-00081 3 225 418 647
( FR940405-1-00081 9 227 737 762 784 810 838 979 1136 1193
pbpk FR940405-1-00081 5 228 239 291 664 711
) FR940405-1-00081 8 229 739 764 793 812 840 983 1140
would FR940405-1-00081 5 231 653 698 713 974
preferred FR940405-1-00081 1 233
advantage FR940405-1-00081 1 236
stems FR940405-1-00081 1 241
its FR940405-1-00081 1 243
biologically FR940405-1-00081 3 244 258 646
motivated FR940405-1-00081 1 245
structure FR940405-1-00081 2 246 648
which FR940405-1-00081 8 248 577 590 597 666 697 935 998
permits FR940405-1-00081 1 249
direct FR940405-1-00081 1 251
incorporation FR940405-1-00081 1 252
biochemical FR940405-1-00081 1 254
constrained FR940405-1-00081 1 259
comparison FR940405-1-00081 1 260
model FR940405-1-00081 10 262 322 409 431 502 523 567 588 652 665
predictions FR940405-1-00081 1 263
experimental FR940405-1-00081 1 265
timecourses FR940405-1-00081 1 266
investigate FR940405-1-00081 1 268
issues FR940405-1-00081 2 270 723
doserate FR940405-1-00081 1 272
effects FR940405-1-00081 1 273
exposureroute FR940405-1-00081 1 275
differences FR940405-1-00081 2 276 1151
pharmacodynamic FR940405-1-00081 1 278
processes FR940405-1-00081 1 279
other FR940405-1-00081 2 282 1147
nonlinearities FR940405-1-00081 1 284
457 FR940405-1-00081 1 288
described FR940405-1-00081 2 299 641
both FR940405-1-00081 6 301 441 582 636 879 957
rats FR940405-1-00081 2 302 347
4112 FR940405-1-00081 2 306 329
4255 FR940405-1-00081 1 308
humans FR940405-1-00081 2 311 558
4270 FR940405-1-00081 2 317 571
physiological FR940405-1-00081 4 321 531 579 1191
disposition FR940405-1-00081 1 325
was FR940405-1-00081 4 331 401 461 472
developed FR940405-1-00081 2 332 576
analyze FR940405-1-00081 1 334
intravenous FR940405-1-00081 3 335 448 553
infusion FR940405-1-00081 7 336 382 387 399 554 613 623
bolus FR940405-1-00081 3 342 397 449
dosing FR940405-1-00081 3 343 400 450
general FR940405-1-00081 1 350
observed FR940405-1-00081 1 353
profiles FR940405-1-00081 2 356 495
blood FR940405-1-00081 3 358 610 620
tissues FR940405-1-00081 4 360 374 460 498
were FR940405-1-00081 2 361 971
consistent FR940405-1-00081 2 362 463
linear FR940405-1-00081 2 364 592
distribution FR940405-1-00081 1 369
into FR940405-1-00081 2 372 1186
all FR940405-1-00081 2 373 693
appeared FR940405-1-00081 1 375
roughly FR940405-1-00081 1 378
threefold FR940405-1-00081 1 379
greater FR940405-1-00081 1 380
following FR940405-1-00081 6 381 386 396 552 611 621
than FR940405-1-00081 1 385
clearance FR940405-1-00081 2 393 1036
significantly FR940405-1-00081 1 402
different FR940405-1-00081 1 403
more FR940405-1-00081 1 406
recent FR940405-1-00081 1 407
rat FR940405-1-00081 2 408 501
255 FR940405-1-00081 1 413
featured FR940405-1-00081 1 415
provided FR940405-1-00081 1 432
successful FR940405-1-00081 1 434
plasma FR940405-1-00081 4 438 754 775 858
intraarterial FR940405-1-00081 1 446
or FR940405-1-00081 2 447 861
timecourse FR940405-1-00081 1 455
most FR940405-1-00081 3 459 707 1011
also FR940405-1-00081 3 462 504 574
; FR940405-1-00081 4 468 761 809 836
necessary FR940405-1-00081 3 473 700 872
include FR940405-1-00081 3 475 529 878
saturable FR940405-1-00081 1 479
brain FR940405-1-00081 2 484 900
heart FR940405-1-00081 2 486 902
lung FR940405-1-00081 2 489 904
adequately FR940405-1-00081 1 491
reproduce FR940405-1-00081 1 492
concentration FR940405-1-00081 1 494
these FR940405-1-00081 3 497 876 959
scaled FR940405-1-00081 1 506
predicting FR940405-1-00081 1 510
mouse FR940405-1-00081 1 511
human FR940405-1-00081 4 513 522 566 639
pharmacokinetics FR940405-1-00081 1 514
recently FR940405-1-00081 1 525
expanded FR940405-1-00081 1 527
well FR940405-1-00081 2 536 615
forearm FR940405-1-00081 1 539
compartment FR940405-1-00081 2 540 890
now FR940405-1-00081 1 544
able FR940405-1-00081 1 545
describe FR940405-1-00081 1 547
4266 FR940405-1-00081 1 562
another FR940405-1-00081 1 565
includes FR940405-1-00081 2 578 995
descriptions FR940405-1-00081 1 580
assumes FR940405-1-00081 1 591
predicts FR940405-1-00081 1 595
results FR940405-1-00081 3 596 805 1048
agree FR940405-1-00081 1 598
published FR940405-1-00081 1 600
6. FR940405-1-00081 1 627
application FR940405-1-00081 2 628 709
modeling FR940405-1-00081 4 631 712 1110 1166
estimation FR940405-1-00081 3 635 740 765
above FR940405-1-00081 1 642
possess FR940405-1-00081 1 643
reasonable FR940405-1-00081 1 645
either FR940405-1-00081 1 651
provide FR940405-1-00081 1 654
useful FR940405-1-00081 3 656 708 1091
starting FR940405-1-00081 1 657
point FR940405-1-00081 1 658
development FR940405-1-00081 1 661
examining FR940405-1-00081 1 672
relationship FR940405-1-00081 1 674
between FR940405-1-00081 1 675
body FR940405-1-00081 1 679
fluids FR940405-1-00081 1 680
inhaled FR940405-1-00081 1 682
neither FR940405-1-00081 1 687
currently FR940405-1-00081 1 691
possesses FR940405-1-00081 1 692
features FR940405-1-00081 2 696 873
appear FR940405-1-00081 1 714
support FR940405-1-00081 1 718
four FR940405-1-00081 2 722 1187
related FR940405-1-00081 1 724
: FR940405-1-00081 2 736 1189
1 FR940405-1-00081 1 738
contribution FR940405-1-00081 1 743
saliva FR940405-1-00081 3 756 777 860
urine FR940405-1-00081 3 758 779 862
nonsmokers FR940405-1-00081 4 760 792 830 1055
2 FR940405-1-00081 1 763
plausible FR940405-1-00081 1 768
upper FR940405-1-00081 1 769
bound FR940405-1-00081 1 770
identify FR940405-1-00081 1 786
individuals FR940405-1-00081 2 787 988
wrongfully FR940405-1-00081 1 788
identifying FR940405-1-00081 1 789
themselves FR940405-1-00081 1 790
viewed FR940405-1-00081 1 798
way FR940405-1-00081 1 801
validate FR940405-1-00081 1 803
misclassification FR940405-1-00081 1 804
derived FR940405-1-00081 1 806
surveys FR940405-1-00081 1 808
3 FR940405-1-00081 1 811
evaluation FR940405-1-00081 3 813 841 1094
impact FR940405-1-00081 3 817 845 963
high FR940405-1-00081 1 819
affinity FR940405-1-00081 1 820
capacity FR940405-1-00081 1 823
4 FR940405-1-00081 1 839
uncertainty FR940405-1-00081 10 848 922 931 994 1018 1046 1088 1097 1115 1172
variability FR940405-1-00081 4 850 1099 1143 1174
infer FR940405-1-00081 1 864
individual FR940405-1-00081 4 866 1141 1153 1155
's FR940405-1-00081 1 867
accomplishing FR940405-1-00081 1 875
analyses FR940405-1-00081 1 877
inhalation FR940405-1-00081 1 880
oral FR940405-1-00081 1 882
routes FR940405-1-00081 1 883
salivary FR940405-1-00081 1 889
evaluating FR940405-1-00081 2 907 1161
two FR940405-1-00081 2 919 944
kinds FR940405-1-00081 1 920
must FR940405-1-00081 1 923
kind FR940405-1-00081 2 929 992
embraces FR940405-1-00081 1 932
those FR940405-1-00081 2 933 996
factors FR940405-1-00081 4 934 946 997 1013
tend FR940405-1-00081 2 937 999
bias FR940405-1-00081 1 939
estimate FR940405-1-00081 2 942 1008
are FR940405-1-00081 2 947 1017
cases FR940405-1-00081 1 960
ignoring FR940405-1-00081 1 965
if FR940405-1-00081 1 969
overestimate FR940405-1-00081 1 977
therefore FR940405-1-00081 1 981
least FR940405-1-00081 1 986
broaden FR940405-1-00081 1 1001
confidence FR940405-1-00081 1 1003
interval FR940405-1-00081 1 1004
category FR940405-1-00081 1 1016
fraction FR940405-1-00081 1 1021
converted FR940405-1-00081 1 1024
free FR940405-1-00081 1 1026
rates FR940405-1-00081 1 1031
metabolic FR940405-1-00081 1 1033
example FR940405-1-00081 1 1043
reported FR940405-1-00081 1 1049
halflives FR940405-1-00081 1 1051
4184 FR940405-1-00081 1 1065
4186 FR940405-1-00081 1 1067
showing FR940405-1-00081 1 1070
mean FR940405-1-00081 1 1072
16.2 FR940405-1-00081 1 1074
hours FR940405-1-00081 1 1075
coefficient FR940405-1-00081 1 1079
variation FR940405-1-00081 1 1081
0.22 FR940405-1-00081 1 1083
7. FR940405-1-00081 1 1085
distinguish FR940405-1-00081 1 1096
relates FR940405-1-00081 1 1103
using FR940405-1-00081 1 1108
assessment FR940405-1-00081 1 1113
defined FR940405-1-00081 1 1118
possible FR940405-1-00081 1 1121
error FR940405-1-00081 1 1122
estimating FR940405-1-00081 2 1124 1168
`` FR940405-1-00081 2 1126 1137
true FR940405-1-00081 1 1127
'' FR940405-1-00081 2 1128 1139
value FR940405-1-00081 1 1129
parameter FR940405-1-00081 1 1132
representative FR940405-1-00081 1 1135
average FR940405-1-00081 1 1138
hand FR940405-1-00081 1 1148
represents FR940405-1-00081 1 1150
purpose FR940405-1-00081 1 1159
usefulness FR940405-1-00081 1 1163
various FR940405-1-00081 1 1177
parameters FR940405-1-00081 2 1178 1192
grouped FR940405-1-00081 1 1185
classes FR940405-1-00081 1 1188
volumes FR940405-1-00081 1 1194
flows FR940405-1-00081 1 1196
